Notably, TNF-α is a proatherogenic cytokine [45] because blockade of TNF-α with biological therapy (infliximab, adalimumab) diminished severity of UC or CD [46] and enhanced the endothelial dysfunction in IBD patients [47]. The gene discussed is TNF; the disease is inflammatory bowel disease.